Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:12 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
NCT06160609 · GlaxoSmithKline · PHASE1/PHASE2 · terminated · last registry update 2024-03-12 · Multiple myeloma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated due to lack of efficacy.” | Open Targets' class: negative | Registry record, GlaxoSmithKline |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFRSF17 in multiple myeloma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-03-03Also stopped (withdrawn): Jack Khouri, MD, Siltuximab + Teclistamab(FDA-approved) (NCT06352866)
- 2024-12-27Results posted on the registry: Janssen Scientific Affairs, LLC, Cilta-cel + Lymphodepleting Therapy (Cyclophosphamide and Fludarabine) (NCT05347485)
- 2024-09-27Results posted on the registry: Pfizer, Elranatamab (PF-06863135) (NCT04798586)
- 2024-09-19Results posted on the registry: Pfizer, Elranatamab (NCT05228470)
- 2024-07-30Results posted on the registry: Pfizer, Elranatamab (NCT05014412)
- 2024-04-02Results posted on the registry: Janssen Research & Development, LLC, JNJ-68284528 (NCT03548207)
- 2024-01-17Phase 3 first posted: Janssen Research & Development, LLC, Talquetamab + Pomalidomide (NCT06208150)
- 2023-11-30Phase 3 first posted: Pfizer, Elranatamab + Elotuzumab (NCT06152575)
- 2023-10-25Results posted on the registry: Pfizer, Elranatamab (PF-06863135) (NCT04649359)
- 2023-10-19Also stopped (terminated): Kite, A Gilead Company, KITE-585 + Cyclophosphamide (NCT03318861)
- 2023-09-21Phase 3 first posted: Celgene, idecabtagene vicleucel + Lenalidomide (NCT06045806)
- 2023-09-21Also stopped (terminated): Precision BioSciences, Inc., PBCAR269A + Fludarabine (NCT04171843)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision